75 results about "Appetite Suppression" patented technology

Disclosed herein is a system to stimulate at least a part of the vestibular system of a patient to induce a sensation of anorexia to promote weight loss. The system can include a thermal element, a power source, a conduit, and a control unit configured to regulate the temperature of the thermal element, the duration in which the thermal element is applied, the duration in between thermal stimuli, and / or the number of stimulus cycles to promote a sensation of anorexia in a patient while avoiding or minimizing undesirable side effects such as nausea, vomiting, nystagmus, or vertigo. Methods of using the system are also disclosed.

The invention involves a medication for weight loss by means of appetite suppression and a method for administering this medication to humans and other mammals. The medication comprises potassium butyrate or closely related chemical compounds, together with chemicals which facilitate the dispersion of the medication in the stomach.

Methods are disclosed for treating a patient with Type 2 diabetes to decrease hypoglycemic episodes and / or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. Further disclosed is a method of suppressing appetite in a patient with Type 2 diabetes comprising administering to the subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. In preferred embodiments, the food composition is in the form of a bar.

The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.

The invention provides a peptide comprising the amino acid sequence given below, together with use of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity. Xaa1 Xaa2 Xaa3 Gly4 Thr5 Phe6 Thr7 Ser8 Asp9 Tyr1O Ser1 1 Lys12 Tyr13 Leu14 Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Trp25 Leu26 Xaa27 Xaa28Xaa29 Xaa30 Xaa31 Xaa32 Lys33 Asn34 Asn35 Ue36 Ala37; wherein: Xaa1 is His1 or D-His1, Xaa2 is Ser2 or Ala2, Xaa3 is Gln3 or Asp3; Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is: G1u1 5 Glu16 G1u17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Glu16 Glu17 Leul18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Glu16 Glu17 Leul18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Glu16 Glu17 Ilel18 Val19 Lys20Tyr21 Phe22 Ile23 Glu24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Gln16 G1u17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu2 3 Gln24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ue23 Gln24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24, or Asp15 Ser16 Arg17 Arg18Ala19 Gln20 Asp21 Phe22 Val23 Gln24; Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is: Met27 Asn28 Thr29 Lys30 Arg31 Asn32, Lys27 Asn28 Ala29 Gly30 Pro31 Ser32, or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32 or a pept ide as set out above in which residue Asn34 is replaced with Asp34; or a peptide as set out above in which Xaa3 is Glu3.

A dried fruit composition enhanced with herbal extracts and a healthful dose of bacteria for enhanced laxative effects and appetite suppression. Preferred methods of manufacture and methods for oral administration of the dried fruit composition are further disclosed.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.

The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity.Xaa1 Xaa2 Xaa3 Gly4 Thr5 Phe6 Thr7 Ser8 Asp9 Tyr10Ser11 Lys12 Tyr13 Leu14 Xaa15 Xaa16 Xaa17 Xaa18Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Trp25 Leu26Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Lys33 Asn34Asn35 Ile36 A1a37;wherein:Xaa2 is His1 or D-His1,Xaa2 is Ser2 or Ala2,Xaa3 is Gln3 or Asp3;Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22Xaa23 Xaa24 is:Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22Leu23 Glu24,Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22Leu23 Gln24,Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22Ile23 Glu24,Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22Ile23 Gln24,Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22Leu23 Glu24,Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22Leu23 Gln24,Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22Ile23 Glu24,Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22Ile23 Gln24,Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22Leu23 Glu24,Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22Leu23 Gln24,Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22Ile23 Glu24,Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22Ile23 Gln24,Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22Leu23 Glu24,Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22Leu23 Gln24,Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22Ile23 Glu24,Glu15 Gln16 Glu17 lle18 Val19 Lys20 Tyr21 Phe22Ile23 Gln24,orAsp15 Ser16 Arg17 Arg18 Ala19 Gln20 Asp21 Phe22Val23 Gln24;Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:Met27 Asn28 Thr29 Lys30 Arg31 Asn32,Lys27 Asn28 Ala29 Gly30 Pro31 Ser32,orLys27 Asn28 Gly29 Gly30 Pro31 Ser32or a peptide as set out above in which residue Asn34 is replaced with Asp34;or a peptide as set out above in which Xaa3 is Glu3;with the proviso that ifXaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22Xaa23 Xaa24 isAsp15 Ser16 Arg17 Arg18 Ala19 Gln20 Asp21 Phe22Val23 Gln24,thenXaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is notMet27 Asn28 Thr29 Lys30 Arg31 Asn32.

The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a GLP-1 receptor agonist, or a regimen of GLP-1 receptor agonist comprising a plurality of substantially evenly spaced doses. The effective dose or regimen does not induce substantial nausea or appetite suppression in the patient.

Compositions for appetite suppression and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a tablet, such as a single or multi-layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. In a preferred embodiment, the compositions contain herbal agents that are anti-appetite agents. The composition is generally effective for suppressing appetite for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa.

A multi-component compound for the simultaneous treatment of nicotine addiction and the side effects of nicotine withdrawal, such as excessive appetite. The first component is a bivalent negative sulfur compound in an amount effective to control nicotine craving or the withdrawal symptoms resulting from nicotine withdrawal. The bivalent negative sulfur is selected from a group that includes, but is not limited to, alkyl sulfides, colloidal sulfur, hydropersulfides, organic thio compounds or their salts. The second component is a serotonin precursor, such as tryptophan or its derivative 5-HTP, which is used to assist the body in producing more serotonin which in turn suppresses appetite. The appetite suppressant(s) are combined with the bivalent negative sulfur compound(s) to provide a single compound that reduces nicotine craving and simultaneously suppresses increased appetite resulting from nicotine withdrawal.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

A method for the appetite suppression of an individual comprising the steps of introducing a bulking material between the vagal nerve area and the stomach wall of a patient undergoing appetite suppression treatment to reduce production levels of ghrelin in the patient's system.

The present invention is double-maltol vanadium complex granule and capsule as diabetes treating medicine and their application. The medicine contains double-maltol vanadium complex as active component, and in the active complex double-maltol chelates vanadium to form five-element unsaturated vanadium-containing ring and vanadium is made to coordinate with oxygen, sulphur or nitrogen, preferablyoxygen. The medicine granule and capsule contains the active component as well as medicinal allowable supplementary material. The present invention is the development and extension of US patent No.5300496. The compound in the effective amount may be used in lower blood sugar and blood circulation as well as in inhibiting appetite for obesity and regulating cholesterol and triglyceride. The granule and the capsule with loose structure may be dissolved, diffused and absorbed to act.

An extraction method for extracts of Pelargonium citronellum with improved methylhexaneamine content is provided. The method involves separating the oil phase from the aqueous phase; concentrating the aqueous phase; purifying the oil phase; and recombining the resulting material. Additionally, extracts of Pelargonium citronellum prepared by the extraction method are provided. The extracts are useful in compositions, for example as dietary supplements, and for appetite suppression.

A method for making the potassium, sodium and other hygroscopic salts of (−)-hydroxycitric acid and mixtures thereof workable by initial treatment with a desiccating agent, such as fumed silicon dioxide. These may be further rendered non-hygroscopic and non-reactive in acidic media via subsequent encasement in hydrophobic and acidophobic polymers. The calcium and magnesium salts of (−)-hydroxycitric acid likewise can be rendered nonreactive in acidic media. The resulting products are suitable for tableting, encapsulation and use in other dry media for weight loss, appetite suppression, improvements in fat metabolism and postprandial lipemia and other pharmaceutical purposes. Further, the products of this invention can be made nonreactive as components of acidic liquid drink mixes and snack bars and can be used in the production of controlled release administration formats.

Prostamides such as bimatoprost and its pro-drugs for enhancement of leptin production and appetite suppression.

The present invention provides for compositions and related methods using extracts from the Cissus quadrangularis plant to improve and eliminate various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. Controlled university studies demonstrated that 300 mg Cissus quadrangularis plant extract provided to obese humans daily for six weeks was effective to provide numerous health benefits including weight loss, improving the bodies fat burning mechanisms, increasing serum serotonin levels which causes appetite suppression and prevents binge eating and / or emotional eating, reducing total cholesterol, LDL cholesterol, triglyceride levels, fasting blood sugar levels and blood pressure, and increasing HDL or “good” cholesterol levels. Additional university controlled experiments also showed that extracts from the Cissus quadrangularis plant were effective in increasing lipase inhibition, α-amylase inhibition, α-glucosidase inhibition in rodents and that large doses of Cissus quadrangularis plant extracts were not toxic to rodents.

The present invention provides a composition of dietary fiber supplements for satiety enhancement and appetite suppression in treatment of overweight, obesity, or eating disorders. The composition of the dietary fiber supplements consist of at least one cationic polymer and at least one anionic polymer. The cationic polymers and the anionic polymers in the composition can be dissolved or dispersed in an aqueous solution. When the pH of the aqueous solution is lowered, such as the solution is ingested into the stomach with a gastric pH environment or the aqueous solution is added with some acidifying agents, the aqueous solution will turn into a gel. The formation of a gel from the aqueous solution after it being ingested into the stomach before a meal would provide a satiety enhancement and appetite suppression effect.

Methods of enabling or improving the ability of a hydrogel to swell in the stomach of an animal and / or increasing the amount of time said hydrogel remains swollen in the stomach are described herein. In one embodiment, a polymer is administered in combination with one or more pH modifying agents which raise and maintain the pH of the micro environment of the polymer and / or the stomach in order inducing swelling in the polymer. The polymer can be a homopolymer, a copolymer, or a polymer blend or composite. In one embodiment, the polymer is a superabsorbent polymer (''SAP''). The polymers can also be administered with one or more active agents, such as appetite suppressants. The pH modifying agent and / or the active agent can be administered simultaneously with the polymer in the same dosage form, simultaneously with the polymer in separate dosage forms, or sequentially. The compositions are formulated for oral administration. The formulation can include drugs for delivery to the stomach, such as antibiotics, or the hydrogel can be used as filler, for example, for obesity control. The formulation an also be used to enhance gastric retention, for example, for controlled drug delivery. Methods of delivering a drug are also described herein, along with medicaments for carrying out the methods of the present invention.

The invention relates to novel a high-volume swelling hydrogel which comprises a plurality of pores which are defined by an interpenetrating network, and / or a semi-interpenetrating network and / or simple cross-linked arrangement of a plurality of one or more species of hydrophilic polymers, optionally together with one or more biocompatible polymers and optionally together with one or more plasticising agents, characterised in that at least some of the pores are at least partially collapsed and / or flattened, and further characterised in that the interpenetrating network and / or semi-interpenetrating network and / or cross-linked arrangement which defines the collapsed and / or flattened pores is substantially unbroken. The invention also relates to a process for preparing such hydrogels, and to their use as an appetite suppressant.

The present invention relates to polypeptides obtained from bear derivative isolate which are useful in suppressing appetite. The polypeptides of the present invention are most preferably between 12 and 13 amino acid residues in length and a mass of about 1249. The present invention also relates to a method of treating obesity by administering to obese subjects an effective amount of the polypeptides of the present invention.

An appetite suppressant composition that is effective for the control of mammalian weight and methods of administration of the composition of the invention are provided. The composition is a cellulose product prepared with ethanol preferably with added sweetener, spice(s), salt and protein for oral administration to a patient.

The invention involves a preparation for the weight loss by means of appetite suppression and a method for administering the preparation to humans and other mammals.A preparation consists of a variety of different spices, sugars, and salts as well as a proteins and alcohols.